Showing 7601-7610 of 8824 results for "".
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study report
- South Florida Women's Shelter Dedicates Shade Structureshttps://practicaldermatology.com/news/south-florida-womens-shelter-dedicates-shades-structures/2460992/Aid to Victims of Domestic Abuse, Inc. (AVDA) in Delray Beach, FL dedicated its new shade structure at the Casa Vegso Residential Campus last month. The structure was funded by an American Academy of Dermatology Shade Structure Grant and SafeSun, Inc., a nonprofit organization dedicated to the pr
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- National Rosacea Society Awards 2021 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2021-research-grants/2460988/The National Rosacea Society has awarded funding for two new studies in addition to continuing support for two ongoing studies as part of its
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is